Category: prescription drugs

KFF Health News’ ‘What the Health?’: The Health of the Campaign

The 2024 presidential race is taking on a familiar tone — with Democrats accusing Republicans of wanting to ban abortion and repeal the Affordable Care Act and Republicans insisting they have no such plans. Voters will determine whom they believe. Meanwhile, for the second time in a month, a state judge overturned an abortion ban, but few expect the decision to settle the matter. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Anna Edney of Bloomberg News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Lauren Sausser, who reported and wrote the latest KFF Health News-Washington Post “Bill of the Month,” about a teenage athlete whose needed surgery lacked a billing code.

KFF Health Tracking Poll September 2024: Support for Reducing Prescription Drug Prices Remains High, Even As Awareness of IRA Provisions Lags

More than two years ago President Biden signed into law Medicare drug pricing provisions in the Inflation Reduction Act. KFF’s September Health Tracking Poll examines voter’s views on these provisions and finds that large majorities of voters are unawa…

Allowing Medicare to Negotiate Drug Prices Remains Broadly Popular Among Voters, Though Most Are Unaware of the Law and Its Projected Savings

Allowing Medicare to negotiate drug prices on behalf of older Americans remains broadly popular across partisans, though many voters are unaware of the new law and the billions of dollars it is expected to save in 2026, a new KFF Health Tracking Poll f…

For Pharma, Trump vs. Harris Is a Showdown Between Two Industry Foes

Vice President Kamala Harris is seen as more aggressive than former President Donald Trump in taking on pharmaceutical companies, but Trump allies say he would also make lowering drug costs a top priority.

The First-Ever Government Negotiation Process for Drugs Has Finished, But the Politics Are Ongoing

This post for Health Affairs Forefront examines how the results of the first-ever Medicare drug price negotiations will generate savings for the government and for Medicare beneficiaries, and how candidates’ views on the issue could play a role in the …

How many people with employer-sponsored insurance use the drugs slated for Medicare price negotiations

A new KFF analysis examines the number of enrollees in the employer-sponsored insurance market who use one or more of the ten drugs selected for Medicare Part D price negotiations. Among the 167 million people with employer-sponsored insurance in 2022,…

While Medicare Drug Price Negotiations Don’t Apply to Private Insurance, 3.4 Million People with Employer Coverage Take at Least One of the Selected Drugs

Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations.

How Many People with Employer-Sponsored Insurance Use the Drugs Slated for Medicare Price Negotiations

Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations, according to a new analysis. The most used drug for people with employer-sponsored h…

How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices

As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”

Compare Trump and Harris Health Care Records and Positions

The side-by-side comparison tool provides a quick overview of former President Trump’s and Vice President Harris’ records, positions, public statements, and proposed policies on a range of key health care topics.